Intrinsiqq
Kala Pharmaceuticals, Inc. logo

Kala Pharmaceuticals, Inc.

KALA

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$7K
EPS-$924.90
P/E-0.00
P/FCF-0.00
EV/EBITDA0.34
FCF Yield–
Div. Yield–
Net Debt/FCF0.4x
Kala Pharmaceuticals, Inc. intrinsic value
52-Week Range
$2.71$7.80

Profitability & Returns

Revenue (FY)

$0.00

Net Income (TTM)

-$10M

▲ +29.9% YoY

Op. Margin

–

ROIC

-79.24%

▼ -46.7pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$20M

▼ -8.9% YoY

Op. Cash Flow (TTM)

-$20M

▼ -8.9% YoY

Net Debt

-$7M

Net Cash Position

Cash & Equiv.

$7M

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with KALA

CompareIntrinsic value
PRPHProPhase Labs Inc.
$0.01-42.00%0
TRDAEntrada Therapeutics Inc.
$4.35-6.25%10
TXMDTherapeuticsMD, Inc.
$1.71-5.52%29
LPCNLipocine Inc.
$1.50+0.00%40
ATAIAtaiBeckley Inc.
$0.53-25.36%40
CNTBConnect Biopharma Holdings Ltd.
$0.59-6.05%10
MRKRMarker Therapeutics, Inc.
$1.11-15.91%25
PSTVPlus Therapeutics Inc
No recent price20

Kala Pharmaceuticals (KALA) in three numbers

Quality score
10/100
Best check: net debt, -$7M. Weakest: return on capital, -79.2%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-0.00
Negative: a loss over the last twelve months. Price to free cash flow -0.00.
Financials

Questions about Kala Pharmaceuticals

Is Kala Pharmaceuticals a high-quality business?

Kala Pharmaceuticals scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$7M, and its weakest is return on capital at -79.2%. The Quality tab shows every check against its target.

Does Kala Pharmaceuticals (KALA) pay a dividend?

No. Kala Pharmaceuticals (KALA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 19 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in KALA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing KALA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.